Overview of Dr. Yu
Dr. Helena Yu is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from University of Michigan Medical School and has been in practice 10 years. She is one of 464 doctors at Memorial Sloan Kettering Cancer Center and one of 88 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. She has more than 100 publications and over 500 citings.
Office
Memorial Sloan Kettering Cancer Center New York
1275 York Avenue
New York, NY 10021- Is this information wrong?
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
- University of Pennsylvania Health SystemResidency, Internal Medicine, 2007 - 2010
- University of Michigan Medical SchoolClass of 2007
Certifications & Licensure
- FL State Medical License 2021 - Present
- NY State Medical License 2010 - 2025
- NJ State Medical License 2020 - 2025
- PA State Medical License 2007 - 2010
Clinical Trials
- Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer Start of enrollment: 2004 Aug 01
- Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer Start of enrollment: 2013 Oct 15
- Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib Start of enrollment: 2014 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.Monica F Chen, Zihe Song, Helena A Yu, Lecia V Sequist, Christine M Lovly, Edith P Mitchell, Jeffrey A Moscow, Robert J Gray, Victoria Wang, Lisa M McShane, Larry V Ru...> ;JCO Precision Oncology. 2024 Apr 1
- Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort St...D'Aiello, A., Owen, D. H., Amin H Nassar, So Yeon Kim, Jacqueline V Aredo, Jamie Feng, Frances Shepherd, Chao Xu, David Kaldas, Jhanelle E Gray, Thomas J Dilling, Joel...> ;Journal of Thoracic Oncology. 2024 Jan 24
- HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced-mutated NSCLC after a third-generation EGFR TKI.Tony Mok, Pasi A Jänne, Makoto Nishio, Silvia Novello, Martin Reck, Conor Steuer, Yi-Long Wu, Ronan Fougeray, Pang-Dian Fan, Jie Meng, David W Sternberg, Stephen Esker...> ;Future Oncology. 2024 May 1
- Join now to see all
Journal Articles
- Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients with Metastatic EGFR-Mutant Lung CancersHelena A Yu, Adam J Schoenfeld, Jamie E Chaft, Gregory J Riely, JAMA Oncology
- Cell-Free DNA NGS Prediction of Response and Resistance to a 3rd-Generation EGFR InhibitorAlexander I Spira, Helena A Yu, Clinical Lung Cancer
- YES1 Amplification Is a Mechanism of Acquired Resistance to EGFR Inhibitors Identified by Transposon Mutagenesis and Clinical GenomicsEmmet J Jordan, Helena A Yu, Yelena Y Janjigian, Mark G Kris, Paul K Paik, Jamie E Chaft, Lu Wang, Gregory J Riely, Proceedings of the National Academy of Sciences
Lectures
- A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers.2019 ASCO Annual Meeting - 6/1/2019
- Sequencing Agents in the Management of EGFR Mutation Positive Non-Small Cell Lung Cancer2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Authored Content
- Cell-Free DNA NGS Prediction of Response and Resistance to a 3rd-Generation EGFR InhibitorAugust 2018
Press Mentions
- Leaders in Breast and Lung Cancer Treatment Join SystImmune Inc's Clinical Science Advisory CommitteeApril 26th, 2023
- Dissolving Knowledge Gaps Regarding EGFR Exon 20 Insertion-Mutant NSCLCJuly 6th, 2022
- 'Brutal, Relentless' Lung Cancer Kills Dustin Diamond: What Are the Symptoms?February 2nd, 2021
- Join now to see all
Hospital Affiliations
- Memorial Sloan Kettering Cancer CenterNew York, New York
- Memorial Hospital for Cancer and allied DiseasesBasking Ridge, New Jersey
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: